Clinical implications of serum Mac-2-binding protein (M2BPGi) during regular follow-up of patients with biliary atresia

Ueno, Takehisa; Kodama, Tasuku; Noguchi, Yuki; Saka, Ryuta; Takama, Yuichi; Tazuke, Yuko; Bessho, Kazuhiko; Okuyama, Hiroomi

doi:https://doi.org/10.1007/S00383-018-4317-2

Clinical implications of serum Mac-2-binding protein (M2BPGi) during regular follow-up of patients with biliary atresia

Ueno, Takehisa; Kodama, Tasuku; Noguchi, Yuki et al.

Pediatric Surgery International, 2018, 34(10), 1065-1071

アクセス数:93件（2025-05-14 03:44 集計）

固定URL: https://hdl.handle.net/11094/96470

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日
PediatrSurgInt_34_10_1065	pdf	なし	302 KB	45	2024.06.28
PediatrSurgInt_34_10_1065_figure	pdf	なし	138 KB	18	2024.06.28
PediatrSurgInt_34_10_1065_table	pdf	なし	199 KB	17	2024.06.28

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Clinical implications of serum Mac-2-binding protein (M2BPGi) during regular follow-up of patients with biliary atresia
著者	NRID 1000010456957 1000010456957 ORCID 0000-0002-4639-8814 0000-0002-4639-8814 researchmap permalink ueno-pedsurg ueno-pedsurg Scopus Author ID 21743992300 21743992300 著者名 Ueno, Takehisa
	著者名 Kodama, Tasuku
	著者名 Noguchi, Yuki
	NRID 1000000459190 1000000459190 ORCID 0000-0001-8960-8618 0000-0001-8960-8618 researchmap permalink sakaryuta sakaryuta 著者名 Saka, Ryuta
	NRID 1000050467560 1000050467560 researchmap permalink tytyty_ytytyt tytyty_ytytyt 著者名 Takama, Yuichi
	NRID 1000010397698 1000010397698 researchmap permalink yukotazuke-osaka yukotazuke-osaka Scopus Author ID 7006109798 7006109798 ORCID 0000-0002-8335-0414 0000-0002-8335-0414 著者名 Tazuke, Yuko
	NRID 1000080423169 1000080423169 著者名 Bessho, Kazuhiko
	NRID 1000030252670 1000030252670 researchmap permalink okuyamahiroomi okuyamahiroomi Scopus Author ID 35496082300 35496082300 ORCID 0000-0002-1347-282X 0000-0002-1347-282X 著者名 Okuyama, Hiroomi
キーワード等	APRI
	Biliary atresia
	FIB-4
	Liver fibrosis
	Liver transplantation
内容	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/S00383-018-4317-2
抄録	Purpose: The Mac-2-binding protein glycosylation-modified isomer (M2BPGi) is a new marker for progression of hepatic fibrosis. We examined the relationship between serum M2BPGi levels and liver histological findings in patients with biliary atresia (BA) who were not transplant candidates. Methods: Patients with BA who were not transplant candidates with good liver function were included. We examined M2BPGi levels and histological findings in relation to other laboratory markers of liver fibrosis, including aspartate aminotransferase (AST) to platelet ratio index, fibrosis-4 index, and type IV collagen 7s domain. Liver fibrosis was evaluated based on the METVIR score. Results: 37 patients were included. The median age was 18 years (range 3–38 years). M2BPGi values ranged from 0.3 to 6.9 cutoff index (COI) (median 1.6). The degree of liver fibrosis varied with M2BPGi level. For predicting cirrhosis (F4) and advanced liver fibrosis (≥ F3), M2BPGi had higher areas under the curve (AUCs; 0.93, respectively) with cutoff COIs of 1.84 and 1.67, respectively, than for the four conventional markers for fibrosis. Conclusion: M2BPGi is a novel marker for liver fibrosis in patients with BA. It is especially useful for following patients with BA with a native liver and supporting liver biopsy interpretation findings.
出版者	Springer Verlagservice@springer.de
収録物名	Pediatric Surgery International
巻(号)	34(10)
ページ	1065-1071
刊行年月	2018-10-01
言語	英語
ハンドルURL	https://hdl.handle.net/11094/96470
PISSN	01790358
eISSN	14379813
関連情報 (isVersionOf)	DOI (出版社版) https://doi.org/10.1007/S00383-018-4317-2
アクセス権	open access
権利情報	© 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
出版タイプ	Accepted Manuscript
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCTERMS.bibliographicCitation	Pediatric Surgery International. 2018, 34(10), p. 1065-1071
DC.title	Clinical implications of serum Mac-2-binding protein (M2BPGi) during regular follow-up of patients with biliary atresia
DC.creator	Ueno, Takehisa
	Kodama, Tasuku
	Noguchi, Yuki
	Saka, Ryuta
	Takama, Yuichi
	Tazuke, Yuko
	Bessho, Kazuhiko
	Okuyama, Hiroomi
DC.publisher	Springer Verlagservice@springer.de
DC.language' scheme='DCTERMS.RFC1766	英語
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2018-10-01
DC.identifier	https://doi.org/10.1007/S00383-018-4317-2
DC.subject	APRI
	Biliary atresia
	FIB-4
	Liver fibrosis
	Liver transplantation
DC.description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/S00383-018-4317-2
DCTERMS.abstract	Purpose: The Mac-2-binding protein glycosylation-modified isomer (M2BPGi) is a new marker for progression of hepatic fibrosis. We examined the relationship between serum M2BPGi levels and liver histological findings in patients with biliary atresia (BA) who were not transplant candidates. Methods: Patients with BA who were not transplant candidates with good liver function were included. We examined M2BPGi levels and histological findings in relation to other laboratory markers of liver fibrosis, including aspartate aminotransferase (AST) to platelet ratio index, fibrosis-4 index, and type IV collagen 7s domain. Liver fibrosis was evaluated based on the METVIR score. Results: 37 patients were included. The median age was 18 years (range 3–38 years). M2BPGi values ranged from 0.3 to 6.9 cutoff index (COI) (median 1.6). The degree of liver fibrosis varied with M2BPGi level. For predicting cirrhosis (F4) and advanced liver fibrosis (≥ F3), M2BPGi had higher areas under the curve (AUCs; 0.93, respectively) with cutoff COIs of 1.84 and 1.67, respectively, than for the four conventional markers for fibrosis. Conclusion: M2BPGi is a novel marker for liver fibrosis in patients with BA. It is especially useful for following patients with BA with a native liver and supporting liver biopsy interpretation findings.
DC.rights	© 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
DC.format	96470
citation_title	Clinical implications of serum Mac-2-binding protein (M2BPGi) during regular follow-up of patients with biliary atresia
citation_author	Ueno, Takehisa
	Kodama, Tasuku
	Noguchi, Yuki
	Saka, Ryuta
	Takama, Yuichi
	Tazuke, Yuko
	Bessho, Kazuhiko
	Okuyama, Hiroomi
citation_publisher	Springer Verlagservice@springer.de
citation_language	英語
citation_date	2018-10-01
citation_journal_title	Pediatric Surgery International
citation_volume	34
citation_issue	10
citation_firstpage	1065
citation_lastpage	1071
citation_doi	https://doi.org/10.1007/S00383-018-4317-2
citation_public_url	https://hdl.handle.net/11094/96470

Clinical implications of serum Mac-2-binding protein (M2BPGi) during regular follow-up of patients with biliary atresia

閲覧可能ファイル

論文情報

論文詳細を表示